Bio-Rad Laboratories (FRA:BUWA) Moat Score: 6/10 (As of Jul. 05, 2026)


FRA:BUWA Bio-Rad Laboratories Inc FRA:BUWA
72 GF Score
Price €257.60
GF Value €275.94
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Bio-Rad Laboratories Moat Score?

Bio-Rad Laboratories FRA:BUWA -0.39% 72 Moat Score is 6 as of Jul. 05, 2026. GuruFocus rates FRA:BUWA with a GF Score™ of 72/100 and a GF Value™ of €275.94 (Fairly Valued). The stock has 5 warning signs investors should review. Among 845 Medical Devices & Instruments companies, Bio-Rad Laboratories ranks better than 95.74% on this metric.

Bio-Rad Laboratories has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Bio-Rad Laboratories has Narrow Moat: Bio-Rad Laboratories Inc has a strong narrow moat due to its valuable IP, strong brand, and customer loyalty in the life sciences sector. However, it faces competition that limits its pricing power and market share.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Bio-Rad Laboratories might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Bio-Rad Laboratories  (FRA:BUWA) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Bio-Rad Laboratories Moat Score Related Terms

FRA:BUWA vs GKOS, BRKR, PODD: Moat Score Comparison

For the Medical Devices subindustry, Bio-Rad Laboratories's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Rad Laboratories Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's Moat Score distribution charts can be found below:

* The bar in red indicates where Bio-Rad Laboratories's Moat Score falls into.


FRA:BUWA
72GF Score
Bio-Rad Laboratories Inc FRA:BUWA
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
Bio-Rad Laboratories (FRA:BUWA) has a Moat Score of 6 as of Jul. 05, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Bio-Rad Laboratories ranks #36 out of 845 companies in the Medical Devices & Instruments industry, placing it in the top 4.3%.
Is Bio-Rad Laboratories' Moat Score too high?
Bio-Rad Laboratories' current Moat Score is 6. Based on the distribution chart, Bio-Rad Laboratories ranks #36 out of 845 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bio-Rad Laboratories has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bio-Rad Laboratories' Moat Score compare to GKOS and BRKR?
According to the Medical Devices & Instruments industry distribution chart, Bio-Rad Laboratories ranks #36 out of 845 companies for Moat Score. This places Bio-Rad Laboratories in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Bio-Rad Laboratories's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Rad Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Bio-Rad Laboratories (FRA:BUWA) is currently considered Fairly Valued. The stock's GF Value™ is €275.94, compared to a current price of €257.60 — trading 6.6% below its estimated fair value. The current Moat Score is 6. Bio-Rad Laboratories' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Bio-Rad Laboratories (FRA:BUWA), the current Moat Score is 6 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bio-Rad Laboratories (FRA:BUWA) Overvalued in 2026?

Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be undervalued. The current stock price of €257.60 is trading 6.6% below its estimated GF Value™ of €275.94. GuruFocus considers Bio-Rad Laboratories to be Fairly Valued.

Key valuation signals for FRA:BUWA:

  • Moat Score: 6
  • GF Value™: €275.94 vs. price of €257.60 (6.6% below fair value)
  • GF Score™: 72/100 with 5 warning signs

No single metric tells the full story. See the FRA:BUWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bio-Rad Laboratories Business Description

Address 1000 Alfred Nobel Drive, Hercules, CA, USA, 94547
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
72GF Score

Get the complete analysis for FRA:BUWA

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€257.60
Price
€275.94
GF Value